The market had been waiting for weeks for Sanofi to come out of the woods. It is done. As investors had hoped, the French pharmaceutical giant has raised the annual sales forecast for its star drug, Dupixent, from 10 to “more than 13 billion euros” per year in pace. cruising. The announcement came just before Sanofi held an investor briefing in the United States on its immunology portfolio, including Dupixent. The group plans to quadruple its turnover in immunology (5.5 billion euros in 2021) by 2030.
Dupixent is Sanofi’s main blockbuster. Eczema, prurigo, but also severe asthma, this treatment by injection targets all these type 2 inflammatory diseases. In this field of immunology, Sanofi has been working for ten years in collaboration with the American Regeneron Pharmaceuticals.
–
